MPR was founded with the idea to provide solutions that are as non-invasive as possible for the treatment of diseases that have an impact on respiratory function. The aim of the company is the continuous research for innovative solutions to develop therapeutic treatments that respect the physiologic parameters involved in the process of breathing and airways clearance, limiting the contraindications often linked to traditional therapies.
EFA® technology
In 2009, after many years of research, we developed another patented technology called EFA® (Expiratory Flow Accelerator), which is employed in the new product FREE ASPIRE ADVANCED, for home care use, and in the device SUCTION FREE, for hospital use. In addition, we have integrated this technology into the cough assist machines KALOS and KINEX, with the idea of increasing the treatment effectiveness through a combined use of the two therapies. This innovative technology accelerates the expiratory flow, promoting deep drainage and secretions removal in patients with ineffective cough, without applying any pressure in the airways. The secretions safely reach the upper airways where the patient can expel or ingest them in a physiological way through the mechanism of the mucociliary system.
